Immunotherapy trial offers new hope for Tough-to-Treat bile duct cancers
NCT ID NCT02829918
Summary
This study tested whether the immunotherapy drug nivolumab could help control advanced bile duct cancer that had stopped responding to standard chemotherapy. The trial enrolled 54 adults whose cancer had progressed after one or two prior treatments. Researchers measured whether tumors shrank and how long patients lived without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.